Sorted By:


America's Pharma Industry Supports Passage of Korea-U.S. Free Trade Agreement

PhRMA  |  Report

The Korea-U.S. (KORUS) Free Trade Agreement is the most commercially significant free trade agreement the United States has engaged in since NAFTA. By reducing and eliminating both tariff and non-tariff barriers to trade between Korea and the United States, the agreement will play a key role in s...

Trends in Weighted Average Sales Prices for Prescription Drugs in Medicare Part B, 2006-2014

PhRMA  |  Report

Research on the pricing of prescription drugs tends to focus on individual products, rather than the overall pricing trend for the market as a whole. This larger trend—which is influenced by multiple competitive forces, including competition among products in therapeutic classes and entry of gene...

A Comparative Analysis of the Role and Impact of Health Technology Assessment

PhRMA  |  Report

Over the last ten years, Health Technology Assessment (HTA) has become an increasingly important part of the assessment system for new medicines. It is generally agreed that HTA has the potential to assist payers in making informed decisions about allocating resources (including expenditure on me...

Questions and Answers for Peer Speakers Program for Health Care Professionals

PhRMA  |  Report

PhRMA companies are deeply committed to responsible, ethical interactions with healthcare professionals, as evidenced by the strengthened PhRMA Code, their robust compliance programs, and their recent support of related legislation, such as the Physician Payment Sunshine provision in the healthcare reform law.

Research in Connecticut

PhRMA  |  Research In Your Backyard

This report shows that biopharmaceutical research companies continue to be vitally important to the economy and patient health in Connecticut, despite the recession.

Twenty-Five Years of Progress Against Hepatitis C: Setbacks and Stepping Stones

PhRMA  |  Report

Hepatitis C is a devastating viral disease which progresses slowly over time and causes very serious damage to the liver. The disease is the leading cause of liver cancer and the most common reason for liver transplant. Today, there are 75 medicines to treat hepatitis C in development in ...

Ebola: The Biopharm Industry Committed to Advancements

PhRMA  |  Report

Researchers around the world, from both the public and private sectors, are increasingly working collaboratively to develop new ways to prevent the spread of Ebola and treat patients who have contracted the virus. The research and development process for new medicines is a lengthy, challenging an...

Follow the Dollar Graphics

PhRMA  |  From PhRMA

View the full report here and the executive summary here.

Quantifying Improvements in Life Quality of Individuals with Complex Chronic Medical Conditions Over the Past Decade

PhRMA  |  Report

Over the past decade, biopharmaceutical researchers have leveraged new technologies and growing scientific knowledge about disease mechanisms to develop sophisticated and comprehensive treatments to complex medical conditions. This paper seeks to analyze and highlight the extent of progress that ...

How drug importation schemes could increase U.S. law enforcement burdens

PhRMA  |  Blog Post

With large-scale importation proposals, we can’t ignore the danger of overwhelming already overburdened law enforcement agencies with increased counterfeit products, including opioids.

Research In Your Backyard

PhRMA  |  From PhRMA

Click any state below to access the full report for that state.

Trade Facilitation and Enforcement Act will strengthen IP enforcement

PhRMA  |  Blog Post

Among the many items in the bill are two of particular importance to biopharmaceutical innovators and the patients they serve: -One establishes a presidentially appointed Chief Innovation and Intellectual Property Negotiator in USTR, who will conduct trade negotiations and enforce trade agreements with respect to U.S. intellectual property as well as take appropriate actions to address foreign acts, policies, and practices with a significant adverse impact on the value of U.S. innovation; -The other establishes a National Intellectual Property Rights Coordination Center to prevent the import and export of infringing goods and requires CBP to work with intellectual property owners to make sure that counterfeit goods will be properly identified and disposed.

New Study: Substantial rebates negotiated in Medicare Part D

PhRMA  |  Blog Post

This report is further evidence of the robust negotiating power of Part D plans and how they secure rebates and discounts to keep costs low for beneficiaries and taxpayers.

What they are saying: Rising deductibles and out-of-pocket costs in health insurance plans

PhRMA  |  Blog Post

Associated Press reported following another recent report from Kaiser Family Foundation.

Director of Application Support and Business Intelligence – Information Technology

PhRMA  |  PhRMA Career

Professional Experience / Requirements  Bachelor’s degree or equivalent knowledge and experience; Experience with financial management and CRM systems; Experience in creating queries, reports, and dashboards using native reporting tools, SSRS, and Power BI; Excellent interpersonal, written and verbal communication skills; Ability to explain technical concepts to a non-technical audience; Ability to handle multiple responsibilities in a dynamic environment; Ability to work across departmental boundaries; Must be available as needed after hours and on weekends to facilitate planned maintenance as well as address emergency problems.

Ask About Adherence: How poorly managed blood pressure is placing older Americans at risk for heart disease and stroke

PhRMA  |  Blog Post

Some of the report’s key findings include: Approximately 70 percent of U.S. adults age 65 and older have high blood pressure.

Director – Federal Advocacy

PhRMA  |  PhRMA Career

The Director will focus primarily on lobbying members of the United States Congress, specifically House Democrats and their staff on issues of import to patients and the pharmaceutical industry.

Medicines in Development for Arthritis, 2014

PhRMA  |  Graphic


Without Significant Reforms 340B Will Continue to Grow As Uninsured Rate Declines

Chartpack  |  From Our Network

340B policies and structure require fundamental reform.

Are insurers exaggerating medicine costs to justify premium increases? Consumers think so.

PhRMA  |  Blog Post

It’s a dramatic decline from the 8.5 percent increase that Altarum reported last year and the 12.5 percent annual increase the year before that.

Forecasts of Specialty Drug Spending Have Been Routinely Overstated

Chartpack  |  From Our Network

A recent analysis of annual drug trend reports found that inconsistent and arbitrary definitions of “specialty medicines” can bias spending projections.

PhRMA Statement Following Meeting With President Trump

PhRMA  |  Press Release

To do this, we need to reform existing laws and regulations that are currently preventing private companies from negotiating better deals and paying for medicines based on the value they provide to patients and our health care system.

Johnson & Johnson, Pfizer, Walgreens and other CEOs discuss value in the future of health care

PhRMA  |  Blog Post

Paz, executive vice president and chief medical officer, Aetna Driving Progress Moderator: Anna Edney, health regulation reporter, Bloomberg Panelists: Amy Abernethy, chief medical officer, chief scientific officer & senior vice president, oncology, Flatiron Health Mark McClellan, Robert J.

Brooke Ringel

PhRMA  |  Biography

Prior to joining PhRMA in June 2013, Brooke practiced international trade law at Kelley Drye & Warren LLP in Washington, specializing in export control and compliance.

340B Spotlight: ICYMI – AJC looks at how some Georgia hospitals are profiting off 340B

PhRMA  |  Blog Post

As part of her research, the reporter spoke with physicians to get their take on the program.

You have reviewed the first 300 results out of 1029. Each page contains 25 results. You're on page 12.

prev 7 8 9 10 11 12 next